Polyrizon Signed An Agreement With Nurexone For Intranasal Administration Of Therapy For Spinal Cord Injuries. BZ NOTE: Medigus Owns 37.03% Of Polyrizon
Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries
Polyrizon will be entitled for up to $3.35 million in addition to future